Bioscience

HTG Names Fredrick Pollock VP of Corporate Development

November 25, 2008

By Flinn Foundation

[Source: BUSINESS WIRE] – HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA(TM)) system and service partner for the life sciences industry, today announced it has appointed Fredrick L. Pollock to Vice President of Corporate Development. Pollock will be responsible for leading commercial sales efforts in the academic and research markets, spearheading efforts for bio-marker and signature discovery collaborations and supporting commercialization efforts for the company’s mid-density array product line.

Over the past eight years, Pollack has served in management, sales and business development roles most recently as Director of Strategic Businesses and Translational Medicine at Affymetrix, Inc., a leading microarray technology vendor. His accomplishments include implementing a global alliance management program, developing strategies for sales expansions, launching several partner clinical laboratory improvement amendments (CLIA) certified clinical tests, and securing multi-millions in additional sales.

“Fred brings a wealth of industry knowledge and expertise to our leadership team and he will help us accelerate our commercial and corporate development efforts,” said TJ Johnson, President and CEO, HTG. “HTG’s portfolio strategy is to leverage the precision of the qNPA assay into the mid-plex market and establish the assay as a new standard for gene expression based diagnostics. Fred’s background is perfectly suited to help us in these specific areas.”

“I am eager to work with the HTG management team and build on the proven success of HTG’s platform to further expand the company’s customer base,” said Fred Pollock. “With my biotechnology and translational medical industry experience this was an ideal fit. I look forward to contributing to HTG’s future success in my new capacity.”

Prior to Affymetrix, Pollock worked at Amersham Pharmacia Biotech, now part of GE Healthcare, for 11 years. He most recently served as a business unit manager where he was responsible for managing sales in the central United States. He also held positions at The University of Texas Southwestern Medical Center and Photon Marketing.

Pollock earned a B.A. in Molecular Biology from the University of North Texas.

HTG’s qNPA technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG’s platform allows scientists to test any sample, including fixed tissues, while avoiding the need for extraction or target amplification. The platform provides high-quality quantitative test results enabling clients to compress drug discovery and development program timelines, increase program success and reduce costs.